GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » Cyclically Adjusted PB Ratio

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Cyclically Adjusted PB Ratio : 2.76 (As of Jun. 05, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-05), Rocket Pharmaceuticals's current share price is $22.23. Rocket Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $8.04. Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 2.76.

The historical rank and industry rank for Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

RCKT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 4.88
Current: 2.73

During the past years, Rocket Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 4.88. The lowest was 0.00. And the median was 0.00.

RCKT's Cyclically Adjusted PB Ratio is ranked worse than
63.33% of 660 companies
in the Biotechnology industry
Industry Median: 1.745 vs RCKT: 2.73

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rocket Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was $4.871. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $8.04 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Rocket Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Rocket Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 3.75

Rocket Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.24 3.06 3.13 3.75 3.35

Competitive Comparison of Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Rocket Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=22.23/8.04
=2.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Rocket Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.871/131.7762*131.7762
=4.871

Current CPI (Mar. 2024) = 131.7762.

Rocket Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 -0.093 100.428 -0.122
201412 -15.094 99.070 -20.077
201503 8.318 99.621 11.003
201506 7.771 100.684 10.171
201509 17.641 100.392 23.156
201512 16.472 99.792 21.751
201603 15.023 100.470 19.704
201606 14.176 101.688 18.370
201609 12.633 101.861 16.343
201612 10.845 101.863 14.030
201703 9.377 102.862 12.013
201706 8.520 103.349 10.864
201709 7.505 104.136 9.497
201712 7.018 104.011 8.891
201803 4.318 105.290 5.404
201806 3.976 106.317 4.928
201809 3.605 106.507 4.460
201812 4.293 105.998 5.337
201903 3.925 107.251 4.823
201906 4.937 108.070 6.020
201909 4.606 108.329 5.603
201912 5.611 108.420 6.820
202003 5.189 108.902 6.279
202006 4.831 108.767 5.853
202009 4.381 109.815 5.257
202012 8.255 109.897 9.898
202103 7.743 111.754 9.130
202106 7.714 114.631 8.868
202109 7.536 115.734 8.581
202112 7.049 117.630 7.897
202203 6.473 121.301 7.032
202206 5.889 125.017 6.207
202209 5.414 125.227 5.697
202212 6.189 125.222 6.513
202303 5.707 127.348 5.905
202306 5.005 128.729 5.123
202309 6.002 129.860 6.091
202312 5.456 129.419 5.555
202403 4.871 131.776 4.871

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rocket Pharmaceuticals  (NAS:RCKT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Rocket Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rocket Pharmaceuticals (Rocket Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Executives
John Militello officer: See Remarks C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Gotham Makker director 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Gaurav Shah director, officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Kinnari Patel officer: Chief Operating Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Mark Andrew White officer: Chief Medical Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
Jonathan David Schwartz officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Martin Wilson officer: General Counsel C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Carlos Garcia-parada officer: Chief Financial Officer C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork director C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam officer: SVP - Finance & PFO 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
David P Southwell director, officer: See Remarks C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Naveen Yalamanchi director 412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Headlines